Tardive dyskinesia

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, July 14, 2022
Tardive dyskinesia, Lists of diseases, Neurocrine Biosciences, Multimedia, AbbVie, LinkedIn, Patient, SAN, Brain, Parkinson's disease, Nasdaq, International, Webcast, Neurocrine, FDA, Twitter, Call, Pharmaceutical industry, Conference, Facebook

SAN DIEGO, July 14, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2022 financial results after the Nasdaq market closes on Thursday, August 4, 2022. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Key Points: 
  • Conference Call and Webcast Scheduled for Thursday, August 4
    SAN DIEGO, July14, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2022 financial results after the Nasdaq market closes on Thursday, August 4, 2022.
  • Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
  • Participants can access the live conference call by dialing 800-895-3361 (US) or 785-424-1062 (International) using the conference ID: NBIX.
  • Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.

Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Retrieved on: 
Wednesday, June 8, 2022
Goldman Sachs, CA, Tardive dyskinesia, Company, Conference, LinkedIn, Parkinson's disease, Nasdaq, Multimedia, Brain, FDA, Goldman, Patient, AbbVie, SAN, Twitter, Neurocrine Biosciences, Lists of diseases, Pharmaceutical industry, Facebook

SAN DIEGO, June 8, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 43rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time) on Wednesday, June 15, 2022 in Rancho Palos Verdes, CA.

Key Points: 
  • SAN DIEGO, June 8, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 43rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time) on Wednesday, June 15, 2022 in Rancho Palos Verdes, CA.
  • Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.
  • The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com .
  • Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

Retrieved on: 
Wednesday, June 8, 2022
Lists of diseases, Seizure, Company, Extrapyramidal symptoms, Perforation, Dysgeusia, Pheochromocytoma, Suicidal ideation, COVID-19, Gastroparesis, Physiology, History, TD, Bronchospasm, Tardive dyskinesia, Metoclopramide, Headache, MBA, Depression, CYP2D6, Methemoglobinemia, Hypertension, Epilepsy, Suicide, EPS, Stomach, Hypersensitivity, Neuroleptic malignant syndrome, Patient, Kidney, Compliance, Private Securities Litigation Reform Act, Catecholamine, Absorption, Parkinsonism, Water, Facebook, Creatinine, NMS, Neoplasm, Fatigue, LinkedIn, United, Hyperprolactinaemia, FDA, GLOBE, Risk, Evoke, NASDAQ, Internal bleeding, Liver, Pharmaceutical industry, Aroma compound, Residential care, Generic drug, Nasdaq

As previously disclosed, in early May, the Company utilized its at-the-market program to raise proceeds of approximately $7.1 million, net of commissions and fees.

Key Points: 
  • As previously disclosed, in early May, the Company utilized its at-the-market program to raise proceeds of approximately $7.1 million, net of commissions and fees.
  • Matt DOnofrio, MBA, Chief Business Officer of Evoke Pharma commented, We are pleased to regain compliance with the Nasdaq listing standards.
  • In conjunction, we are happy to announce that weve substantially bolstered our cash reserves and extended operational runway.
  • We believe the additional capital positions us to sustain and increase GIMOTI sales and to capitalize on future market opportunities.

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022

Retrieved on: 
Monday, May 23, 2022
Tardive dyskinesia, Risk, Allergy, Constipation, Company, Movement, Nausea, Somnolence, Dizziness, Annual general meeting, Parkinson's disease, U.S. Securities and Exchange Commission, Falls, Tongue, VMAT1, Nasdaq, Psychiatry, Lists of diseases, American, AbbVie, Patient, Schizoaffective disorder, Walking, Multimedia, American Psychiatric Association, Treatment, Liver, QT, Torso, Vitamin, COVID-19, Xerostomia, Bipolar disorder, Depression, APA, Capsule, FDA, Neuron, SAN, Brain, Histaminergic, Neurocrine, Neurocrine Biosciences, Vomiting, Dopamine, LinkedIn, Twitter, Poster, Face, Headache, Schizophrenia, TD, Impact, VMAT2, D2, Pharmaceutical industry, Dietary supplement, Liquor, Facebook

"The findings presented at the APA Annual Meeting provide further insight into aspects of tardive dyskinesia management that are important to patients," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.

Key Points: 
  • "The findings presented at the APA Annual Meeting provide further insight into aspects of tardive dyskinesia management that are important to patients," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
  • These data demonstrate that stability of psychiatric symptoms is maintained during TD treatment with valbenazine."
  • The condition is associated with taking certain kinds of mental health medicines (like antipsychotics) that help control dopamine receptors in the brain.
  • Additionally, INGREZZA can be taken for the treatment of tardive dyskinesia as one capsule, once-daily, together with most psychiatric medications such as antipsychotics or antidepressants.

Andrea Hartzell, PhD, of Health & Wellness Partners, LLC Named One of the 2022 PM360 ELITE 100

Retrieved on: 
Friday, May 20, 2022
HWP, Knowledge, Doctor of Philosophy, Patient, Health, Hartzell, University, University of California, San Diego, LLC, TD, Tardive dyskinesia, Management, Medicine, Neuroscience

UPPER SADDLE RIVER, N.J., May 20, 2022 /PRNewswire/ -- Andrea Hartzell, PhD, Scientific Director at Health & Wellness Partners, LLC (HWP), a global medical communications company, was named as one of the 2022 PM360 ELITE 100 in the Master Educator category.

Key Points: 
  • UPPER SADDLE RIVER, N.J., May 20, 2022 /PRNewswire/ -- Andrea Hartzell, PhD, Scientific Director at Health & Wellness Partners, LLC (HWP), a global medical communications company, was named as one of the 2022 PM360 ELITE 100 in the Master Educator category.
  • The PM360 ELITE (Exceptional Leaders Innovators Transformers Entrepreneurs) represents the most influential people in the health care industry today.
  • "Andrea helped develop a brilliantyet simpletool that clinicians can use to screen for TD, which is underdiagnosed and undertreated.
  • The PM360 ELITE 100 awards were established in 2015 to recognize individuals who have made a significant impact on the health care industry throughout their careers.

Evoke Pharma to Present at H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, May 17, 2022
Parkinsonism, NMS, Risk, Creatinine, Physiology, History, Hypersensitivity, Suicide, Dysgeusia, EPS, Kidney, Pheochromocytoma, Seizure, Metoclopramide, Extrapyramidal symptoms, Bronchospasm, Lists of diseases, Patient, Suicidal ideation, NASDAQ, Stomach, Liver, Epilepsy, Internal bleeding, Depression, Methemoglobinemia, FDA, Facebook, Gastroparesis, Catecholamine, Conference, Tardive dyskinesia, Neoplasm, CYP2D6, Water, LinkedIn, Headache, Neuroleptic malignant syndrome, Hyperprolactinaemia, Fatigue, TD, United, Absorption, Hypertension, Perforation, GLOBE, Pharmaceutical industry, Aroma compound, Residential care, Generic drug

In addition, management will be available for one-on-one meetings during the conference.

Key Points: 
  • In addition, management will be available for one-on-one meetings during the conference.
  • Registered investors will be able to request a meeting with management via the conference portal.
  • Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases.
  • Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects.

Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease

Retrieved on: 
Friday, May 13, 2022
Company, Population, Shanda, HD, Parkinson's disease, Chorea, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, U.S. Securities and Exchange Commission, Multimedia, Patient, AbbVie, Degenerative disease, Clinical trial, COVID-19, FDA, SAN, Brain, Time, Neurocrine, Safety, Security (finance), LinkedIn, KINECT, Twitter, Neurocrine Biosciences, Lists of diseases, Tardive dyskinesia, VMAT2, Pharmaceutical industry, Dietary supplement, Facebook, Huntington's disease

SAN DIEGO, May 12, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc.(Nasdaq: NBIX) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for valbenazine as a treatment for Huntington disease (HD).

Key Points: 
  • SAN DIEGO, May 12, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc.(Nasdaq: NBIX) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for valbenazine as a treatment for Huntington disease (HD).
  • The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation.
  • Enrollment is ongoing in the KINECT-HD2 open-label study to evaluate the long-term safety and tolerability of valbenazine for the treatment of chorea in Huntington Disease.
  • KINECT-HD2 is an open-label study to evaluate the long-term safety and tolerability of valbenazine in patients with chorea associated withHuntingtondisease (HD).

Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference

Retrieved on: 
Tuesday, May 3, 2022
Neurocrine Biosciences, Tardive dyskinesia, Company, FDA, Bank, Conference, Brain, Multimedia, Patient, SAN, Nasdaq, Parkinson's disease, AbbVie, List of life sciences, LinkedIn, Pharmaceutical industry

SAN DIEGO, May 3, 2022 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2022 Healthcare Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday, May 10, 2022 in Las Vegas.

Key Points: 
  • SAN DIEGO, May 3, 2022 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2022 Healthcare Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday, May 10, 2022 in Las Vegas.
  • Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.
  • The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com .
  • Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.

Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List

Retrieved on: 
Tuesday, April 19, 2022
Human services, Gastroparesis, COVID-19, Risk, NASDAQ, Perforation, NMS, GLOBE, Patient, LinkedIn, Creatinine, United, Dysgeusia, Absorption, Pheochromocytoma, TD, FDA, Internal bleeding, Liver, Catecholamine, Metoclopramide, MBA, Water, Parkinsonism, Private Securities Litigation Reform Act, Stomach, Physiology, PDL, Extrapyramidal symptoms, Texas Health and Human Services Commission, Kidney, Evoke, Fatigue, CEO, Awareness, Suicidal ideation, Hypertension, Marketing, Methemoglobinemia, U.S. Securities and Exchange Commission, Neuroleptic malignant syndrome, Hypersensitivity, EPS, Tardive dyskinesia, Bronchospasm, DGP, Depression, History, Seizure, Safety, Facebook, Hyperprolactinaemia, Suicide, Neoplasm, Lists of diseases, Headache, CYP2D6, Epilepsy, Pharmaceutical industry, Aroma compound, Residential care, Generic drug, Medicaid

This decision supports reimbursement for GIMOTI on the Texas Medicaid formulary and associated programs which provides healthcare to an estimated 5 million people.

Key Points: 
  • This decision supports reimbursement for GIMOTI on the Texas Medicaid formulary and associated programs which provides healthcare to an estimated 5 million people.
  • According to Texas Health and Human Services, preferred drugs are medications recommended by the Texas Drug Utilization Review Board for their efficaciousness, clinical significance, cost effectiveness, and safety.
  • The Medicaid Formulary contains all products, including those on the preferred drug list, available to people enrolled in Medicaid.
  • GIMOTI will be available for those that fail treatment with any preferred drug class.

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, April 13, 2022
LinkedIn, Neurocrine Biosciences, Tardive dyskinesia, Multimedia, FDA, Brain, AbbVie, Patient, Webcast, Parkinson's disease, Pharmaceutical industry

SAN DIEGO, April 13, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 4, 2022.

Key Points: 
  • The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com .
  • A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
  • Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.
  • We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders.